Human immunodeficiency virus associated lymphoma

Current Opinion in Oncology

Volumn 15, Issue 5, 2003, Pages 372-378

  Sparano, Joseph A ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

AIDS; Highly active antiretroviral therapy; HIV infection; HIV associated lymphoma; Hodkgin disease; Non Hodgkin lymphoma

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; RITUXIMAB; VINCA ALKALOID;

CANCER CHEMOTHERAPY; CANCER RISK; CENTRAL NERVOUS SYSTEM LYMPHOMA; CLINICAL FEATURE; CLINICAL TRIAL; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TOXICITY;

ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, AIDS-RELATED; STEM CELL TRANSPLANTATION;

EID: 0042833018     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200309000-00005     Document Type: Review

References (22)

1. International Collaboration on HIV Infection and Cancer: HAART and incidence of cancer in HIV infected Adults. J Natl Cancer Inst 2000, 92:1823-1830.
2. Mocroft A, Katlama C, Johnson AM, et al.: AIDS across Europe, 1994-98: the EuroSlDA study. Lancet 2000, 356:291-296.
3. Bessen C, Geubar A, Gabarre J, et al.: Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001, 98:2339-2344.
4. Ratner L, Lee J, Tang S, et al.: Chemotherapy for human immunodeficiency virus-associated non-Hodgkin lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001, 19:2171-2178.
5. Henry DH, Sparano JA, Lee S, et al.: Impact of highly active antiretroviral therapy on prognosis in patients with HIV-associated non-Hodgkin lymphoma: an analysis of ECOG trial E1494. Proc Am Soc Clin Oncol 2001, 20, 294a:(abstr 1172).
6. Vaccher E, Spina M, di Gennaro G, et al.: Concomitant cyclophosphamide, doxorubicin and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 2001, 91:155-163.
7. Antinori A, Cingolani A, Alba L, et al.: Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001, 15:1483-1491.
8. Little RF, Pittaluga S, Grant N, et al.: Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003, 101:4653-4659. This phase II study demonstrated EPOCH to be a highly effective regimen for the management of HIV-associated lymphoma; the authors advocated discontinuing HAART therapy during cytotoxic therapy.
9. Matthews GV, Bower M, Mandalia S, et al.: Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000, 96:2730-2734.
10. Carbone A, Gloghini A, Larocca LM, et al.: Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenic subjects of human immunodeficiency virus-related lymphoma. Blood 2001, 97:744-751.
11. Sparano JA, Weller E, Nazeer T, et al.: Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor prognosis intermediate- or high-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493). Blood 2002, 100:1634-1640. This multicenter phase II study evaluated the infusional CDE regimen in immuno-competent patients with poor-risk lymphoma by the IPI index.
12. Wilson WH, Grossbard ML, Pitaluga S, et al.: Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002, 99:2685-2693.
13. Coiffier B, Lepage E, Herbrecht R, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Eng J Med 2002, 346:235-242.
14. Mounier N, Briere J, Gisselbrecht C, et al.: Rituximab plus CHOP (R-CHOP) overcomes bcl-2 associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma. Blood 2003, 101:4279-4284.
15. Subar M, Neri A, Inghirami G, et al.: Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma. Blood 1988, 72:667-671.
16. Kaplan LD, Scadden DT: No benefit from rituximab in a randomized phase III trial of CHOP with or without rituximab for patients with HIV-associated non- Hodgkin lymphoma. AIDS Malignancies Consortium Study 010. Proc Am Soc Clin Oncol 2003, 22:564, 2003:(abstract 2268). This multicenter phase III study reported at the 2002 American Society of Clinical Oncology meeting demonstrated that the addition of rituximab to standard chemotherapy was associated with a significantly increased risk of death due to infection.
17. Boue F, Gabarre J, Gisselbrecht C, et al.: CHOP Chemotherapy plus rituximab in HIV patients with high grade lymphoma - results of an ANRS trial. Blood 2002, 22:470a:(abstract 1824).
18. Spina M, Sparano JA, Jaegaer U, et al.: Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin lymphoma and HIV infection. AIDS 2003, 17:137-138. This multicenter phase II trial demonstrated that rituximab plus infusional CDE was safe and effective.
19. Krishnan A, Molina A, Zaia J, et al.: Autologous stem cell transplantation for HIV-associated lymphoma. Blood 2001, 98:3857-3859.
20. Spina M, Vaccher E, Nasti G, et al.: Human immunodeficiency virus-associated Hodgkin disease. Semin Oncol 2000, 27:480-488.
21. Spina M, Gabarre J, Rossi G, et al.: Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002, 100:1984-1988. This study demonstrated the Stanford V regimen to be effective in HIV-associated Hodgkin disease.
22. Horning SJ, Hoppe RT, Breslin S, et al.: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002, 20:630-637.